To investigate the association between cholesterol-lowering interventions and risk of death from suicide, accident or trauma (non-illness mortality).
How were the studies combined?
A summary odds ratio (OR) and 95% confidence interval (CI) was calculated using the Mantel-Haenszel method, as modified by Yusuf et al. (see Other Publications of Related Interest no.1).
How were differences between studies investigated?
Statistical heterogeneity was assessed using the chi-squared test. Subgroup analyses were conducted on the primary and secondary prevention trials separately, and on clinical trials using statins separate from other interventions. The association of non-illness mortality with the average amount of cholesterol reduction was assessed using a weighted regression model. A model was also fitted excluding studies with no deaths from non-illness-related causes in either or both the treatment and control groups.
Results of the review
Twenty-one RCTs were eligible, of which 19 provided data (70,704 patients).
The mean reduction in cholesterol varied considerably across studies (3.5 to 26%). There was no significant difference in non-illness mortality overall (OR 1.18, 95% CI: 0.91, 1.5, P=0.20). There was no evidence of heterogeneity (chisquared P>0.05).
In the subgroup analyses of primary and secondary prevention trials, no significant increase was shown in non-illnessrelated mortality with cholesterol-lowering treatment. The OR was 1.28 (95% CI: 0.94, 1.74, P=0.12) for primary prevention trials (8 RCTs) and 1.00 (95% CI: 0.65, 1.55, P=0.98) for secondary prevention trials (11 RCTs).
The subgroup analysis of statin trials (5 RCTs) showed no significant increase in non-illness-related mortality (OR 0.84, 95% CI: 0.50, 1.41, P=0.50). Trials of non-statin treatment (13 RCTs) showed an increase in non-illness-related mortality, but this did not reach statistical significance (OR 1.32, 95% CI: 0.98, 1.77, P=0.06).
The regression analysis did not find an association between the mean cholesterol reduction and non-illness mortality (P=0.23).
Authors' conclusions
Currently available evidence does not indicate that non-illness mortality is increased significantly by cholesterollowering treatments. A modest increase may occur with dietary interventions and non-statin drugs.
CRD commentary
The review question was clear in terms of the study design, interventions and outcomes. Limiting the literature to only one database may have resulted in the omission of other relevant studies. It was not stated whether any language restrictions were applied. No details were presented of the methods used to select the studies or extract the data. Hence, the adequacy of the methods used to conduct these processes cannot be assessed. Validity was not formally assessed, and no comment was made on the validity of methods used to record and determine the cause of mortality in the individual studies. Relevant data were extracted and tabulated; the additional tables are available on the BMJ website (accessed 22/09/2003). See Web Address at end of abstract. The studies were appropriately combined in a metaanalysis and statistical heterogeneity was assessed for overall mortality. A subgroup analysis was used to explore the influence of various factors on the results. The evidence presented appears to support the authors' conclusion. This metaanalysis updates a previous review (see Other Publications of Related Interest no.2).
